As defibrillator therapy is invasive and expensive, using a defibrillator as primary prevention therapy requires risk stratification to identify suitable patients at significant risk. In this review Antonis A Armoundaset alevaluate whether clinical data support the use of microvolt T-wave alternans testing to identify patients who are unlikely to benefit from primary prevention implantable cardioverter-defibrillator therapy.
- Antonis A Armoundas
- Stefan H Hohnloser
- Richard J Cohen
